KYOWA HAKKO BIO CO.,LTD.

  • U.S.A
  • Europe
  • Japan
  • Message
  • Business Domain
  • Overview
  • Philosophy
  • Officer
  • History
  • Global Network
  • Plants
  • CSR
  • IR
  • Amino Acids
  • Peptides
  • Nucleic Acids
  • Catalog
  • Vitamins
  • Catalog
  • Contact Us
  • Technical Research Laboratory
  • Bioprocess Development Center
  • Healthcare Products Development Center
  • AminoScope™
  • Contact Us
  • Dipeptides
  • Oligosaccharides & Sugar Nucleotides

News

Kyowa Hakko’s Citicoline obtains Novel Food Registration status in Europe

July 17, 2014

Kyowa Hakko’s Citicoline obtains Novel Food Registration status in Europe

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) delivered a scientific opinion on Citicoline as a novel food ingredient (NFI) and concluded that Citicoline is safe under the proposed uses and use levels (www.efsa.europa.eu/it/efsajournal/doc/3421.pdf ).

Commission Implementing Decision 2014/423/EU of 1 July 2014 authorising Kyowa Hakko Europe the placing on the market of Citicoline as a novel food ingredient under Regulation (EC) No 258/97 (http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:JOL_2014_196_R_0006&from=EN ).

Citicoline is intended to be used in food supplements aimed at adult population at a maximum level of 500 mg/day, and in foods for particular nutritional uses, specifically foods for special medical purposes, at a maximum level of 250 mg/serving, and with a maximum daily intake from these types of foods of 1 000 mg/day.

In United States, Kyowa Hakko USA, Inc. offers a proprietary form of Citicoline, Cognizin®, a pure, allergen-free GRAS ingredient that’s stable and effective. For more information, go to www.cognizin.com .